In a significant move that underscores its commitment to advancing its FDA process, Innocan Pharma Corporation has announced the appointment of Dr. Joseph V. Pergolizzi, Jr., M.D. to its Scientific Advisory Board (SAB). This appointment comes as the company, known for its innovative products, gears up for its upcoming Pre-FDA meeting for human medications.
Dr. Pergolizzi’s credentials are impressive. With a rich background in pain management and critical care medicine, he brings to the table extensive academic, clinical, and business achievements. His experience spans various C-level positions in both private and public healthcare companies. Notably, he has been a Senior Partner at Naples Anesthesia and Pain Associates and has served as the Chief Operating Officer at NEMA Research Inc. His association with the FDA is also noteworthy, having been a former subcommittee member of the FDA SUI and SGE VAH Grant Review for Analgesics.
His research contributions are significant, with over 400 peer-reviewed articles to his name. Topics he has delved into include opioid-induced constipation, cardiotoxicity due to cocaine, and the effects of illicitly manufactured fentanyl. His work has garnered him several accolades, including the Patients Choice Award and the Compassionate Doctor Recognition Award.
Innocan’s focus on the global pain management market, which is poised for significant growth, is expected to benefit immensely from Dr. Pergolizzi’s expertise. His role will primarily revolve around promoting pharmaceutical human product R&D and the company’s FDA processes.
For context, Innocan has been making waves in the pharmaceutical tech domain. Their work in the Pharmaceuticals segment is particularly noteworthy, with a focus on developing innovative drug delivery platform technologies integrated with cannabinoid science. Their research aims to improve patients’ quality of life, especially those suffering from conditions like epilepsy and pain.
Recently, Innocan revealed a clinical study demonstrating the efficacy of their liposomal CBD in reducing osteoarthritis pain in dogs. Published in the Frontiers in Veterinary Science Journal, the research showed that a single injection led to prolonged pain relief and increased activity in affected dogs. This breakthrough suggests that Innocan’s liposomal CBD could be a game-changer in pain management for dogs with osteoarthritis, and beyond.
With these advancements and the addition of Dr. Pergolizzi to their advisory board, Innocan Pharma is undoubtedly positioning itself as a frontrunner in the pharmaceutical tech domain. As they inch closer to FDA approvals, the healthcare industry will be keenly watching their next moves.
The article is not intended to serve as financial or investment advice.